SEC Form 4 · accession 0001179110-17-000824
Tempest Therapeutics, Inc. · TPST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christophe Couturier
Officer — Chief Financial Officer
Period of report
Jan 5, 2017
Accepted (ET)
Jan 9, 2017 · 7:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001544227
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.64 | Jan 5, 2017 | A | 100,000 | A | — | Jan 5, 2027 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The option vests as to 12.5% of the option shares on January 5, 2017 and vests as to an additional 12.5% of the option shares at the end of each successive three-month period thereafter.